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To find a pathogenetic pathway that could serve as a treat-
ment target, we conducted next-generation sequencing on for-
malin-fixed tumour. The test identified the NRAS p.Gln61Arg
mutation with a variant frequency of 8%.
Due to the failure of previous treatments and the major
potential risk of a surgical procedure, we offered the patient
an off-label compassionate treatment with trametinib, a mito-
gen-activated protein kinase kinase (MEK) inhibitor. Following
the patient’s consent, treatment was initiated at a dose of
2 mg once daily. The skin lesions were already reduced
1 week after treatment initiation and regression was almost
complete after 3 months of treatment, with only a subtle rem-
nant in the upper eyelid (Figure 1d).
Follow-up evaluation included blood pressure measurement,
complete blood count, liver and renal function tests, lipid pro-
file, electrocardiography, echocardiogram and ophthalmologi-
cal examination. The adverse effects included acneiform rash,
mild paronychia and asthenia. No severe adverse events were
noted.
Recent seminal discoveries have uncovered the role of
hyperactivation of the RAS–mitogen-activated protein kinase–
extracellular signal-regulated kinase pathway in most vascular
anomalies.1,2 PGs harbour mutations in RAS genes. In previous
studies six specimens out of 42 sporadic PGs showed muta-
tions in KRAS, NRAS or HRAS,3 and four and one specimens out
of 25 PGs arising on port-wine stains showed mutations in
BRAF and KRAS, respectively.4
The differential diagnosis in our case was eruptive dissemi-
nated PG. PGs are usually solitary, but multiple lesions (satelli-
tosis) can occur after initial surgical removal5 or following a
burn.6 Multiple localized PG-like lesions are termed agminated
PGs7 and may follow an aggressive clinical course. Our case
showed a focally superficial component with lobular architec-
ture on pathology and clinical behaviour simulating agminated
PG, in association with diffuse acquired unspecified capillary
haemangioma, a unique pattern previously unreported.
NRAS is one of the three major isoforms of the RAS family
of GTPase proteins. Almost 60% of NRAS tumours harbour
mutations at codon 61, and 35% at codon 12.8
In summary, we report a unique case of reactive aggressive
vascular proliferation simulating agminated PG with NRAS
mutation, and its excellent response to a MEK inhibitor. Our
results highlight the potential of targeted therapies in the con-
text of vascular lesions.
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Minimal, superficial DNA damage in human
skin from filtered far-ultraviolet C
DOI: 10.1111/bjd.19816
DEAR EDITOR, Krypton chloride (KrCl) excimer lamps have a
peak emission wavelength of 222 nm, in the ultraviolet (UV)
C region of the electromagnetic spectrum. Currently KrCl
lamps are the only viable ‘far-UVC’ sources for full-room
inactivation of airborne SARS-CoV-2, the virus responsible for
the COVID-19 pandemic.1 Commercially available KrCl exci-
mer lamps can be retrofitted to existing room lamp fittings or
mounted at ceiling height independently. Other technologies,
such as light-emitting diodes, are currently neither efficient
nor powerful enough for such a task.
In addition to the peak KrCl excimer emission wavelength
of 222 nm (83% at 200–230 nm), the lamp spectrum con-
tains longer-wavelength UVC (10% at 230–280 nm), UVB
(3%) and UVA radiation (4%). These additional wavelengths
have been shown in vivo and in silico to penetrate to the skin’s
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basal layer and cause DNA damage.2,3 When the excimer lamp
was filtered, reducing these longer wavelengths of UV radia-
tion, a study in 20 healthy volunteers did not show erythema
induction 24 h after exposure to 500 mJ cm2.4 In that study
there was a slight, statistically significant, increase in cyclobu-
tane pyrimidine dimers (CPDs) compared with nonirradiated
skin, although the location of these CPDs was not determined.
However, computer modelling and animal experiments sug-
gest that these CPDs will be limited in number and restricted
to the uppermost parts of the epidermis.2,5 The location of
CPDs is important as, if limited to the superficial suprabasal
nonproliferating skin cells, it is unlikely that this will indicate
a carcinogenic risk.6 To our knowledge, the location of CPDs
from filtered far-UVC radiation, as described above, has never
been demonstrated in human skin.
We performed human skin irradiation in two settings using
a filtered KrCl far-UVC source (SafeZoneUVC, Ushio Inc.,
Tokyo, Japan): firstly, in a novel ex vivo full-thickness human
skin model cultured at tension (manuscript in preparation)
and secondly, using in vivo self-exposures. Ex vivo human skin
was obtained from an abdominoplasty after full consent was
obtained. This skin was cultured at the air–liquid interface in
RM + medium containing 50 lg mL1 gentamicin, 200 U
mL1 penicillin, 200 lg mL1 streptomycin and 025
lg mL1 amphotericin B. There were three samples: an unir-
radiated negative control sample, a positive control sample
irradiated for 188 s delivering a radiant exposure of
515 mJ cm2 narrowband UVB (peak emission wavelength
311 nm, TL01; Philips, Eindhoven, the Netherlands) and the
test sample irradiated for 1000 s delivering a radiant exposure
of 6100 mJ cm2 filtered far-UVC. The human skin provider,
Biopredic International, holds permit AC-2013-1754 granted
by the French Ministry of Higher Education and Research for
the acquisition, transformation, sales and export of human
biological material for research.
In vivo, two of the authors irradiated their inner forearms
at a dose of 6100 mJ cm2 of filtered far-UVC, using the
same irradiation source and distance as the ex vivo samples.
Ethical approval was not required for self-exposures in the
two senior investigators who led the in vivo aspects of this
work.
Punch biopsies (4 mm) were taken from irradiated sites
within 30 min of exposure and from nonirradiated sites,
and were fixed in freshly prepared 4% paraformaldehyde at
20°C prior to paraffin embedding. CPD abundance was
revealed by immunohistochemical staining with monoclonal
anti-thymine dimer antibody (T1192; Sigma-Aldrich, St
Louis, MO, USA).
Figure 1 displays histological staining of both the ex vivo and
irradiated in vivo skin. As would be expected, there is CPD for-
mation throughout the epidermis following narrowband UVB
irradiation in the ex vivo skin model (Figure 1b) and no CPDs
in the ex vivo control sample (Figure 1a). Both the ex vivo and
in vivo filtered far-UVC-irradiated human skin samples show
minimal CPD formation (Figure 1c and d, respectively).
Where CPD-positive cells were present in one volunteer,
importantly they were restricted to the upper layers of the epi-
dermis, with no basal-layer CPD formation detected. Fewer
CPD-positive cells were detected in the filtered far-UVC-irradi-
ated skin of the second volunteer, where a thicker stratum
corneum was evident, and both control in vivo samples were
CPD negative (data not shown).
This first-in-human demonstration of CPD location from fil-
tered far-UVC confirms the results of our previous in silico
model and indicates that the peak KrCl excimer emission
wavelength of 222 nm does not penetrate beyond the most
superficial epidermal layers.2 The ex vivo skin model was also
in agreement with the in vivo exposures, enabling us to under-
take future investigations that would be difficult to perform in
humans. The radiant exposure delivered in these experiments
(a) (b)
(c) (d)
Figure 1 Histological staining. (a) Nonirradiated ex vivo skin sample. (b) Narrowband ultraviolet (UV)B-irradiated ex vivo skin sample. (c) Far-UVC-
irradiated ex vivo skin sample. (d) Far-UVC-irradiated in vivo human skin sample. Formalin-fixed paraffin-embedded skin samples were stained for
cyclobutane pyrimidine dimer (CPD) formation using immunohistochemical methods. Arrows are used to highlight examples of CPD-positive cells.
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is 265 times the current exposure limit value of 23 mJ cm2
at 222 nm.7 Therefore, even at very high exposure doses,
appropriately filtered far-UVC is unlikely to present a carcino-
genic risk through direct DNA damage. These important but
preliminary results are very encouraging. As recently advised
and encouraged by the UK’s Scientific Advisory Group for
Emergencies we are continuing with multiple far-UVC
research projects to investigate the efficacy and safety profile
of this very promising technology.8 However, to date, the evi-
dence is overwhelmingly in favour of using filtered far-UVC
as a safe, effective germicidal technology.
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Inducible skin-associated lymphoid tissue
(iSALT) in a patient with Schnitzler syndrome
who manifested wheals on recurrent localized
erythema
DOI: 10.1111/bjd.19808
DEAR EDITOR, Schnitzler syndrome is characterized by a chronic
urticarial rash with an intermittent fever, and is considered to
be an acquired form of autoinflammatory syndrome because
its clinical phenotypes are similar to cryopyrin-associated peri-
odic syndrome with a gain-of-function mutation in NLRP3.1
Patients with Schnitzler syndrome also exhibit IgM mono-
clonal gammopathy, and 15–20% of patients eventually
develop a lymphoproliferative disorder resembling Walden-
str€om macroglobulinaemia with an MYD88 mutation.2 At pre-
sent, the precise pathogenesis of Schnitzler syndrome remains
unknown.3
Chronic inflammation in the skin triggers the develop-
ment of tertiary lymphoid structures, and in a mouse
model, we proposed the term of inducible skin-associated
lymphoid tissue (iSALT) that efficiently activates effector T
cells.4 Subsequently, we showed that some inflammatory
skin diseases in humans can also form iSALT structures, i.e.
formation of the central B-cell zone in lymphoid follicles,
lined with the expression of the B-cell chemoattractant
CXCL13, while in the surrounding T-cell zone, peripheral
lymph node addressin (PNAd)-positive vessels indicating dif-
ferentiation towards high endothelial venules (HEVs) were
observed.5,6 Here, we describe a case of Schnitzler syndrome
that exhibited iSALT with a peripheral distribution of IgM-
expressing plasma cells.
A 63-year-old woman developed an urticarial rash without
pruritus on her left cheek and the right side of her neck (Fig-
ure 1a). She reported a periodic fever of over 38 °C along
with general fatigue. Laboratory findings confirmed leucocyto-
sis [18 440 µL1 (normal range 2700–8500)] with marked
neutrophilia (844%), elevated C-reactive protein [54 mg
dL1 (0–02)] and IgM [1898 mg dL1 (54–333)]. The
patient was diagnosed with Schnitzler syndrome.7 Bone pain
was not apparent. Liver and renal function tests were normal.
Somatic mosaicism in NLRP3 and MYD88 was excluded
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